111 related articles for article (PubMed ID: 32544549)
1. A signature predicting relapse based on integrated analysis on relapse-associated alternative mRNA splicing in I-III rectal cancer.
Zhang Z; Ji M; Lv Y; Feng Q; Zheng P; Mao Y; Xu Y; He G; Xu J
Genomics; 2020 Sep; 112(5):3274-3283. PubMed ID: 32544549
[TBL] [Abstract][Full Text] [Related]
2. Analysis of relapse-associated alternative mRNA splicing and construction of a prognostic signature predicting relapse in I-III colon cancer.
Zhang Z; Feng Q; Jia C; Zheng P; Lv Y; Mao Y; Xu Y; He G; Xu J
Genomics; 2020 Nov; 112(6):4032-4040. PubMed ID: 32645524
[TBL] [Abstract][Full Text] [Related]
3. A novel 16-gene alternative mRNA splicing signature predicts tumor relapse and indicates immune activity in stage I-III hepatocellular carcinoma.
Chen XX; Zhang BH; Lu YC; Li ZQ; Chen CY; Yang YC; Chen YJ; Ma D
Front Pharmacol; 2022; 13():939912. PubMed ID: 36147313
[No Abstract] [Full Text] [Related]
4. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer.
Mo S; Dai W; Xiang W; Li Y; Feng Y; Zhang L; Li Q; Cai G
Carcinogenesis; 2019 Jul; 40(7):861-870. PubMed ID: 30933267
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome profiling reveals an integrated mRNA-lncRNA signature with predictive value of early relapse in colon cancer.
Dai W; Feng Y; Mo S; Xiang W; Li Q; Wang R; Xu Y; Cai G
Carcinogenesis; 2018 Oct; 39(10):1235-1244. PubMed ID: 29982331
[TBL] [Abstract][Full Text] [Related]
6. An integrated mRNA-lncRNA signature for relapse prediction in laryngeal cancer.
Xiang Y; Li C; Liao Y; Wu J
J Cell Biochem; 2019 Sep; 120(9):15883-15890. PubMed ID: 31062433
[TBL] [Abstract][Full Text] [Related]
7. Gene signature is associated with early stage rectal cancer recurrence.
Kalady MF; Dejulius K; Church JM; Lavery IC; Fazio VW; Ishwaran H
J Am Coll Surg; 2010 Aug; 211(2):187-95. PubMed ID: 20670856
[TBL] [Abstract][Full Text] [Related]
8. p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer.
Schwandner O; Schiedeck TH; Bruch HP; Duchrow M; Windhoevel U; Broll R
Eur J Cancer; 2000 Feb; 36(3):348-56. PubMed ID: 10708936
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Survival and Local Relapse Following Surgery Without Radiotherapy for Locally Advanced Upper Rectal Cancer: An International Multi-Institutional Study.
Park JS; Sakai Y; Simon NSM; Law WL; Kim HR; Oh JH; Shan HCY; Kwak SG; Choi GS
Medicine (Baltimore); 2016 May; 95(22):e2990. PubMed ID: 27258487
[TBL] [Abstract][Full Text] [Related]
10. A 16-mRNA signature optimizes recurrence-free survival prediction of Stages II and III gastric cancer.
Peng K; Chen E; Li W; Cheng X; Yu Y; Cui Y; Li Q; Wang Y; Xu X; Tang C; Gan L; Yu S; Liu T
J Cell Physiol; 2020 Jul; 235(7-8):5777-5786. PubMed ID: 32048287
[TBL] [Abstract][Full Text] [Related]
11. [Treatment strategy and pattern evaluation of 314 patients with recurrence of rectal cancer].
Liu YL; Yang YM; Wang XS
Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Aug; 13(8):572-6. PubMed ID: 20737306
[TBL] [Abstract][Full Text] [Related]
12. A robust gene signature for the prediction of early relapse in stage I-III colon cancer.
Dai W; Li Y; Mo S; Feng Y; Zhang L; Xu Y; Li Q; Cai G
Mol Oncol; 2018 Apr; 12(4):463-475. PubMed ID: 29377588
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
14. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
[TBL] [Abstract][Full Text] [Related]
15. Identification of an alternative splicing signature as an independent factor in colon cancer.
Chen H; Luo J; Guo J
BMC Cancer; 2020 Sep; 20(1):904. PubMed ID: 32962686
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Stage I-II Rectal Cancer Patients.
Yoshida D; Minami K; Sugiyama M; Ota M; Ikebe M; Morita M; Matsukuma A; Toh Y
J Surg Res; 2020 Jan; 245():281-287. PubMed ID: 31421374
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Value of Circumferential Resection Margin Involvement in Patients with Extraperitoneal Rectal Cancer.
Shin DW; Shin JY; Oh SJ; Park JK; Yu H; Ahn MS; Bae KB; Hong KH; Ji YI
Am Surg; 2016 Apr; 82(4):348-55. PubMed ID: 27097629
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of a potent multi-mRNA signature for the prediction of early relapse in hepatocellular carcinoma.
Cai J; Tong Y; Huang L; Xia L; Guo H; Wu H; Kong X; Xia Q
Carcinogenesis; 2019 Jul; 40(7):840-852. PubMed ID: 31059567
[TBL] [Abstract][Full Text] [Related]
19. Towards a "Lyon molecular signature" to individualize the treatment of rectal cancer. Prognostic analysis of a prospective cohort of 94 rectal cancers T1-2-3 Nx MO to be the basis of a molecular signature.
Gérard JP; Baulieux J; Doyen J; Gal J; Letouze E; Olschwang S; Chapet O; Romestaing P
Cancer Radiother; 2012 Dec; 16(8):688-96. PubMed ID: 23153504
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors affecting local recurrence and survival for operable rectal cancers.
Kuru B; Camlibel M; Dinç S; Erdem E; Alagöl H
J Exp Clin Cancer Res; 2002 Sep; 21(3):329-35. PubMed ID: 12385573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
